<DOC>
<DOCNO>1051222_business_story_5630407.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 JB Chem lines up subsidiary in Russia

 OUR SPECIAL CORRESPONDENT 

 POP THE PILL

 Mumbai, Dec. 21: JB Chemicals amp; Pharmaceuticals Ltd (JBCPL), a mid-sized pharmaceutical company, is setting up a subsidiary in Moscow with an initial investment of $3 million to widen its reach in the Russian and CIS countries.

 According to the company, it will be a wholly owned subsidiary and will be called 000 Unique Pharmaceuticals Laboratories. 

 Explaining the rationale behind this move, JB Chemicals said that the aggregate retail pharmaceutical market in Russia and CIS countries is valued at around $5.5 billion and it holds huge growth potential. The subsidiary will enable the company increasing its business significantly in Russia and CIS markets, a company spokesperson said.

 JB Chemicals said that close to 45 per cent of its turnover of Rs 370 crore for the year ended March 31, 2005 came from exports to Russia amp; CIS. The company earned an export income of Rs 211.38 crore in 2004-05.

 Commenting on the development, JB Chemicals director D. B. Mody said, The company plans to grow its market share in Russia and CIS countries and maintain its leadership position with the introduction of new products and novel technologies in a much wider therapeutic fields in the near future.

 The entry into Russia comes days after the company bagged the US Food and Drug Administration (US FDA) approval to manufacture and market fluconazole tablets in the US market. Earlier, it received the US regulators approval to manufacture and market ciprofloxacin tablets 250 mg, 500 mg, 750 mg in the US. 

 JB Chemicals now plans to file more abbreviated new drug applications.

 During the second quarter ended September 30, the company achieved net sales of Rs 127.06 crore compared with Rs 103.48 crore in the corresponding period last year, a growth of 23 per cent, driven mainly by higher exports. 




</TEXT>
</DOC>